merged_eli-lilly-zepbound-price.txt
<other>Based on the provided article, I will answer each question in order, adhering strictly to the format and constraints.</other>
<question_number>1</question_number>
<answer>Lilly is positioning its vials as a safer option than compounded drugs.</answer>
<question_number>2</question_number>
<answer>Offering online prescriptions and direct delivery of an FDA-approved product at a lower price.</answer>
<question_number>3</question_number>
<answer>Subject to far less oversight than traditionally approved medications.</answer>
<question_number>4</question_number>
<answer>To regain market share from compounding pharmacies.</answer>
<question_number>5</question_number>
<answer>It is the status that allows compounding pharmacies to make copycat versions.</answer>
<question_number>6</question_number>
<answer>N/A</answer>
<question_number>7</question_number>
<answer>Older patients on Medicare might be drawn to the cheaper vials despite potential risks.</answer>
<question_number>8</question_number>
<answer>By positioning its vials as a safer, FDA-approved option.</answer>
<question_number>9</question_number>
<answer>In shortage.</answer>
<question_number>10</question_number>
<answer>N/A</answer>